Product How it works Pricing Blog FAQ About Contact
United States

Praxis Precision Medicines (NASDAQ: PRAX) stock: the official figures

Praxis Precision Medicines (PRAXIS PRECISION MEDICINES, INC.) is listed on Nasdaq under the ticker PRAX and belongs to the health care sector. In fiscal 2025 it reported revenue of $0.0m and a net loss of $303.3m, according to the annual accounts it filed with the regulator.

Identifiers for Praxis Precision Medicines: SEC CIK 1689548.

Fiscal 2025 figures

Consolidated annual accounts of Praxis Precision Medicines, in millions of US dollars
Item20252024Change
Revenue$0.0m$8.6m−100.0%
Operating profit−$326.2m−$200.2m—
Net profit−$303.3m−$182.8m—
Earnings per share−$13.48−$10.21—
Total assets$937.9m$483.1m+94.1%
Equity$878.1m$445.5m+97.1%
Cash$357.3m$215.4m+65.9%
Operating cash flow−$249.1m−$131.8m—

Margins are calculated from the filed figures: operating profit and net profit over revenue.

7 fiscal years

Revenue, in millions of US dollars0.020222.420238.620240.02025Net profit, in millions of US dollars-35.52019-61.82020-167.12021-214.02022-123.32023-182.82024-303.32025
Fiscal yearRevenueOperating profitNet profitEarnings per shareDocument
2025$0.0m−$326.2m−$303.3m−$13.48Annual report
2024$8.6m−$200.2m−$182.8m−$10.21Annual report
2023$2.4m−$126.4m−$123.3m−$18.69Annual report
2022$0.0m−$215.0m−$214.0m−$4.64Annual report
2021—−$167.3m−$167.1m−$3.94Annual report
2020—−$62.0m−$61.8m−$7.86Annual report
2019—−$35.8m−$35.5m—Annual report

The full income statement, balance sheet and cash flow statement are in the annual accounts of Praxis Precision Medicines. Purchases and sales by its executives and directors are in insider transactions.

Members of Congress who traded Praxis Precision Medicines

In the congressional reports read up to 9 November 2026, 1 member has disclosed 2 transactions in Praxis Precision Medicines: Gilbert Ray Cisneros, Jr. (2).

Frequently asked questions about Praxis Precision Medicines

How much did Praxis Precision Medicines earn in fiscal 2025?
Praxis Precision Medicines reported a net loss of $303.3m for fiscal 2025, on revenue of $0.0m. The year before it reported a net loss of $182.8m.
What are the earnings per share of Praxis Precision Medicines?
They were −$13.48 in fiscal 2025, compared with −$10.21 the year before.
Where is Praxis Precision Medicines listed?
Praxis Precision Medicines is listed on Nasdaq under the ticker PRAX and belongs to the health care sector.
Where do the figures for Praxis Precision Medicines come from?
From the annual report (Form 10-K) that Praxis Precision Medicines files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

The annual accounts come from the annual report (Form 10-K) that Praxis Precision Medicines files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.